Peptides
Tirzepatide vs. the GLP-1 Field: What the Switching Data Actually Shows
Patients are shuffling between Ozempic, dulaglutide, and tirzepatide. A small case series and a new biosimilar trial offer the first grounded signals on how this class is fragmenting — and what switching really looks like.